Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF.

Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.

2.

The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain.

Breivogel CS, Puri V, Lambert JM, Hill DK, Huffman JW, Razdan RK.

J Recept Signal Transduct Res. 2013 Dec;33(6):367-79. doi: 10.3109/10799893.2013.838787. Epub 2013 Oct 4.

PMID:
24094141
3.

Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

Wiley JL, Marusich JA, Huffman JW.

Life Sci. 2014 Feb 27;97(1):55-63. doi: 10.1016/j.lfs.2013.09.011. Epub 2013 Sep 23. Review.

4.

Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids.

Cox AO, Daw RC, Mason MD, Grabenauer M, Pande PG, Davis KH, Wiley JL, Stout PR, Thomas BF, Huffman JW.

J Anal Toxicol. 2012 Jun;36(5):293-302. doi: 10.1093/jat/bks025.

5.

Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.

Wiley JL, Smith VJ, Chen J, Martin BR, Huffman JW.

Bioorg Med Chem. 2012 Mar 15;20(6):2067-81. doi: 10.1016/j.bmc.2012.01.038. Epub 2012 Jan 30.

6.

1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Wiley JL, Marusich JA, Martin BR, Huffman JW.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):148-53. doi: 10.1016/j.drugalcdep.2011.11.001. Epub 2011 Nov 27.

7.

Hijacking of Basic Research: The Case of Synthetic Cannabinoids.

Wiley JL, Marusich JA, Huffman JW, Balster RL, Thomas BF.

Methods Rep RTI Press. 2011 Nov;2011. pii: 17971.

8.

Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, Huffman JW, Walentiny DM, Vann RE, Razdan RK, Martin BR.

Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. doi: 10.1016/j.ejphar.2010.10.085. Epub 2010 Nov 27.

9.

8-Chloro- and 5,8-Dichloro1-naphthoic Acids.

Chen J, Smith VJ, Huffman JW.

Org Prep Proced Int. 2010;42(5):490-493. No abstract available.

10.

1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.

Huffman JW, Hepburn SA, Lyutenko N, Thompson AL, Wiley JL, Selley DE, Martin BR.

Bioorg Med Chem. 2010 Nov 15;18(22):7809-15. doi: 10.1016/j.bmc.2010.09.061. Epub 2010 Sep 29.

11.

Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.

Huffman JW, Hepburn SA, Reggio PH, Hurst DP, Wiley JL, Martin BR.

Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. doi: 10.1016/j.bmc.2010.06.054. Epub 2010 Jun 22.

12.

Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

Vann RE, Warner JA, Bushell K, Huffman JW, Martin BR, Wiley JL.

Eur J Pharmacol. 2009 Aug 1;615(1-3):102-7. doi: 10.1016/j.ejphar.2009.05.010. Epub 2009 May 23.

13.
14.

Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice.

Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK.

Behav Pharmacol. 2008 Jul;19(4):298-307. doi: 10.1097/FBP.0b013e328308f1e6.

15.

Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor.

Marriott KS, Huffman JW.

Curr Top Med Chem. 2008;8(3):187-204. Review.

PMID:
18289088
16.

CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Rajesh M, Mukhopadhyay P, Haskó G, Huffman JW, Mackie K, Pacher P.

Br J Pharmacol. 2008 Jan;153(2):347-57. Epub 2007 Nov 12.

17.

Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.

Poso A, Huffman JW.

Br J Pharmacol. 2008 Jan;153(2):335-46. Epub 2007 Nov 5. Review.

18.

Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.

Huffman JW, Thompson AL, Wiley JL, Martin BR.

Bioorg Med Chem. 2008 Jan 1;16(1):322-35. Epub 2007 Sep 22.

19.

CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P.

Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8. Epub 2007 Jul 27.

20.

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury.

Bátkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, Hong F, Harvey-White J, Jafri A, Haskó G, Huffman JW, Gao B, Kunos G, Pacher P.

FASEB J. 2007 Jun;21(8):1788-800. Epub 2007 Feb 27.

21.

1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.

Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR.

Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. Epub 2006 Aug 4.

PMID:
16889960
23.

Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor.

Huffman JW, Bushell SM, Joshi SN, Wiley JL, Martin BR.

Bioorg Med Chem. 2006 Jan 1;14(1):247-62. Epub 2005 Sep 13.

PMID:
16165365
24.

CB2 receptor ligands.

Huffman JW.

Mini Rev Med Chem. 2005 Jul;5(7):641-9. Review.

PMID:
16026310
25.

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.

Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR.

Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3.

PMID:
16005223
26.

Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.

Huffman JW, Padgett LW.

Curr Med Chem. 2005;12(12):1395-411. Review.

PMID:
15974991
27.

Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson AL, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR.

Bioorg Med Chem. 2005 Jan 3;13(1):89-112.

PMID:
15582455
28.

Structure-activity relationships for 1',1'-dimethylalkyl-Delta8-tetrahydrocannabinols.

Huffman JW, Miller JR, Liddle J, Yu S, Thomas BF, Wiley JL, Martin BR.

Bioorg Med Chem. 2003 Apr 3;11(7):1397-410.

PMID:
12628666
29.

3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor.

Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, Reggio PH, Wiley JL, Martin BR.

Bioorg Med Chem. 2003 Feb 20;11(4):539-49.

PMID:
12538019
30.

Inhibition of tumor angiogenesis by cannabinoids.

Blázquez C, Casanova ML, Planas A, Gómez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, Aragonés J, Huffman JW, Jorcano JL, Guzmán M.

FASEB J. 2003 Mar;17(3):529-31. Epub 2003 Jan 2.

PMID:
12514108
31.

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.

Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M.

J Clin Invest. 2003 Jan;111(1):43-50.

32.

1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor.

Huffman JW, Bushell SM, Miller JR, Wiley JL, Martin BR.

Bioorg Med Chem. 2002 Dec;10(12):4119-29.

PMID:
12413866
33.

Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.

Anikwue R, Huffman JW, Martin ZL, Welch SP.

J Pharmacol Exp Ther. 2002 Oct;303(1):340-6.

PMID:
12235269
34.

Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity.

Wiley JL, Jefferson RG, Griffin G, Liddle J, Yu S, Huffman JW, Martin BR.

Pharmacology. 2002 Oct;66(2):89-99.

PMID:
12207116
35.

A pyridone analogue of traditional cannabinoids. A new class of selective ligands for the CB(2) receptor.

Huffman JW, Lu J, Hynd G, Wiley JL, Martin BR.

Bioorg Med Chem. 2001 Nov;9(11):2863-70.

PMID:
11597467
36.

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M.

Cancer Res. 2001 Aug 1;61(15):5784-9.

37.

Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding.

Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR.

Drug Alcohol Depend. 2000 Aug 1;60(2):133-40.

PMID:
10940540
38.

The search for selective ligands for the CB2 receptor.

Huffman JW.

Curr Pharm Des. 2000 Sep;6(13):1323-37. Review.

PMID:
10903395
39.

Synthesis and pharmacology of a hybrid cannabinoid.

Huffman JW, Lu J, Dai D, Kitaygorodskiy A, Wiley JL, Martin BR.

Bioorg Med Chem. 2000 Feb;8(2):439-47.

PMID:
10722167
40.

Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L.

Nature. 2000 Mar 2;404(6773):84-7.

PMID:
10716447
41.

3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.

Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR.

Bioorg Med Chem. 1999 Dec;7(12):2905-14.

PMID:
10658595
42.

Retrospective evaluation of urinary tract infection in 42 dogs with hyperadrenocorticism or diabetes mellitus or both.

Forrester SD, Troy GC, Dalton MN, Huffman JW, Holtzman G.

J Vet Intern Med. 1999 Nov-Dec;13(6):557-60.

43.
44.

Cannabimimetic indoles, pyrroles and indenes.

Huffman JW.

Curr Med Chem. 1999 Aug;6(8):705-20. Review.

PMID:
10469887
45.

Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists.

Martin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, Saha B, Razdan RK.

J Pharmacol Exp Ther. 1999 Sep;290(3):1065-79.

PMID:
10454479
46.

Synthesis and pharmacology of the isomeric methylheptyl-delta8-tetrahydrocannabinols.

Huffman JW, Liddle J, Duncan SG Jr, Yu S, Martin BR, Wiley JL.

Bioorg Med Chem. 1998 Dec;6(12):2383-96.

PMID:
9925296
47.

Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC.

Huffman JW, Yu S.

Bioorg Med Chem. 1998 Dec;6(12):2281-8.

PMID:
9925290
48.

Enantioselective synthesis and pharmacology of 11-hydroxy-(1'S,2'R)-dimethylheptyl-delta 8-THC.

Liddle J, Huffman JW, Wiley JL, Martin BR.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2223-6.

PMID:
9873517
49.

Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.

Welch SP, Huffman JW, Lowe J.

J Pharmacol Exp Ther. 1998 Sep;286(3):1301-8.

PMID:
9732392
50.

Structure-activity relationships of indole- and pyrrole-derived cannabinoids.

Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, Martin BR.

J Pharmacol Exp Ther. 1998 Jun;285(3):995-1004.

PMID:
9618400

Supplemental Content

Loading ...
Support Center